Gut-First vs Brain-First Parkinson's Disease Trajectories

Gut-First vs Brain-First Parkinson's Disease Trajectories

The gut-first vs brain-first hypothesis represents one of the most significant conceptual frameworks in modern Parkinson's disease (PD) research. This dual-trajectory model proposes that PD can initiate in two distinct anatomical locations—the gastrointestinal tract or the central nervous system—with fundamentally different pathophysiological mechanisms, clinical presentations, and therapeutic implications.

Introduction

Parkinson's disease, traditionally viewed as a brain-centric neurodegenerative disorder, has increasingly been recognized as a systemic disease with prominent peripheral manifestations. The gut-first vs brain-first hypothesis, first proposed by Hawkes and colleagues in 2007 and subsequently refined by Braak and colleagues, suggests that the pathological process underlying PD may begin in either the enteric nervous system (gut-first) or the brain (brain-first), with distinct propagation patterns and clinical consequences. [@mediterranean]

This framework has profound implications for understanding disease heterogeneity, developing early diagnostic biomarkers, and designing disease-modifying therapies that target the appropriate anatomical compartment at the right stage of disease progression. [@leveraging]

Pathological Mechanisms

The Gut-First (Body-First) Trajectory

Gut-First vs Brain-First Parkinson's Disease Trajectories

The gut-first vs brain-first hypothesis represents one of the most significant conceptual frameworks in modern Parkinson's disease (PD) research. This dual-trajectory model proposes that PD can initiate in two distinct anatomical locations—the gastrointestinal tract or the central nervous system—with fundamentally different pathophysiological mechanisms, clinical presentations, and therapeutic implications.

Introduction

Parkinson's disease, traditionally viewed as a brain-centric neurodegenerative disorder, has increasingly been recognized as a systemic disease with prominent peripheral manifestations. The gut-first vs brain-first hypothesis, first proposed by Hawkes and colleagues in 2007 and subsequently refined by Braak and colleagues, suggests that the pathological process underlying PD may begin in either the enteric nervous system (gut-first) or the brain (brain-first), with distinct propagation patterns and clinical consequences. [@mediterranean]

This framework has profound implications for understanding disease heterogeneity, developing early diagnostic biomarkers, and designing disease-modifying therapies that target the appropriate anatomical compartment at the right stage of disease progression. [@leveraging]

Pathological Mechanisms

The Gut-First (Body-First) Trajectory

In the gut-first model, also termed the "body-first" trajectory, pathological alpha-synuclein aggregation is believed to initiate in the gastrointestinal tract, specifically in the enteric nervous system (ENS). The vagus nerve then serves as the primary conduit for propagating pathological aggregates from the gut to the central nervous system via trans-synaptic spread. [@bibliometric]

Key pathological features of the gut-first trajectory include: [@vitamin]

The Brain-First Trajectory

In the brain-first model, the pathological process initiates within the central nervous system, typically in regions vulnerable to alpha-synuclein aggregation such as the olfactory bulb or the substantia nigra itself. Peripheral manifestations in this trajectory may occur secondary to central pathology rather than serving as the initial trigger. [^6]

Key pathological features of the brain-first trajectory include: [^7]

Alpha-Synuclein Initiation Sites

Gut-Based Initiation

Multiple lines of evidence support the gastrointestinal tract as a site of alpha-synuclein initiation: [^8]

• α-Synuclein in the ENS: Studies have detected phosphorylated alpha-synuclein in the colonic mucosa of patients with PD, even in early disease stages and in prodromal cases.
• REM Sleep Behavior Disorder (RBD): Patients with isolated RBD, a prodromal PD marker, frequently show gastrointestinal abnormalities and reduced vagal tone.
• Gut Microbiota Alterations: Changes in gut microbiota composition have been documented in PD and may contribute to alpha-synuclein misfolding and aggregation in the ENS.
• Appendiceal Evidence: Recent studies have identified the appendix as a potential reservoir for alpha-synuclein pathology, with appendectomy associated with altered PD risk in some populations.

Brain-Based Initiation

Evidence for brain-first initiation includes: [^9]

• Olfactory Dysfunction: Olfactory impairment is one of the earliest prodromal signs of PD and may precede motor symptoms by years.
• Olfactory Bulb Pathology: Alpha-synuclein inclusions are frequently found in the olfactory bulb of PD patients, even in early disease stages.
• Incidental Lewy Body Disease: Some individuals show Lewy body pathology in the brain at autopsy without clinical PD, suggesting that the pathological process can begin in the brain without obvious peripheral involvement.
• Different Prodromal Phenotypes: Not all prodromal PD patients develop gastrointestinal symptoms early, supporting the existence of non-gut-first trajectories.

Propagation Mechanisms

Vagal Nerve Propagation

The vagus nerve (cranial nerve X) serves as the major highway for gut-to-brain propagation in the gut-first trajectory: [^10]

Key evidence for vagal propagation:

• Truncal vagotomy (surgical removal of the vagus nerve) has been associated with reduced PD risk in some epidemiological studies.
• Animal models demonstrate that alpha-synuclein can propagate along the vagus nerve from the gut to the brain.
• The dorsal motor nucleus of the vagus shows some of the earliest Lewy body pathology in gut-first PD.

Neural Circuit Propagation

Alternative propagation mechanisms include:

• Olfactory Pathway: Nasal-to-olfactory bulb propagation in brain-first PD.
• Spinal Cord: Possible propagation via autonomic nerves.
• Blood-Borne Spread: Circulating alpha-synuclein aggregates potentially crossing the blood-brain barrier.

Prodromal Biomarker Differences

The gut-first and brain-first trajectories exhibit distinct prodromal biomarker profiles:

Gut-First (Body-First) Prodromal Markers

| Marker | Expected Pattern |
|--------|------------------|
| Constipation | Early, prominent |
| REM Sleep Behavior Disorder | Common |
| Vagal Tone (HRV) | Reduced early |
| Gut Microbiota | Altered |
| Colon Inflammation | Elevated markers |
| GUT-specific α-Syn | Phosphorylated in ENS |
| Cardiac Sympathetic Innervation | May be preserved early |

Brain-First Prodromal Markers

| Marker | Expected Pattern |
|--------|------------------|
| Olfactory Dysfunction | Early, prominent |
| Mood/Neuropsychiatric Changes | Common early |
| Cognitive Changes | May appear early |
| Olfactory Bulb Volumetry | Reduced |
| Dopaminergic Imaging | Abnormal |
| Cardiac Sympathetic Innervation | Early involvement possible |
| Gut Symptoms | May be absent early |

Key Diagnostic Biomarkers

Clinical Progression Patterns

Gut-First (Body-First) Clinical Course

• Constipation, irritable bowel syndrome
• REM sleep behavior disorder
• Reduced sense of smell (may be mild)
• Depression or anxiety

• Typical PD motor symptoms (tremor, bradykinesia, rigidity)
• Often asymmetric onset
• Good levodopa response
• May develop motor fluctuations over time

• Motor complications
• Non-motor symptoms become prominent
• May progress to dementia

Brain-First Clinical Course

• Olfactory dysfunction (prominent)
• Mood changes (depression, anxiety)
• Mild cognitive changes
• Sleep disturbances

• Tremor-dominant or postural instability/gait difficulty phenotype
• May have different levodopa responsiveness
• More rapid progression in some cases

• Earlier cognitive impairment
• More prominent neuropsychiatric symptoms
• Autonomic dysfunction

Clinical Phenotype Differences

| Feature | Gut-First | Brain-First |
|---------|-----------|-------------|
| Motor Phenotype | Tremor-dominant common | PIGD more common |
| Disease Progression | Slower in some studies | Potentially faster |
| Levodopa Response | Generally good | Variable |
| Motor Complications | Develops over time | May appear earlier |
| Non-Motor Symptoms | GI prominent early | Cognitive/mood early |
| Dementia Risk | Increases with duration | Earlier onset possible |

Diagnostic Implications

Distinguishing Trajectories Clinically

Accurate identification of the trajectory type has important diagnostic implications:

Current Diagnostic Challenges

• No Definitive Test: Currently, trajectory type can only be definitively determined at autopsy.
• Overlap: Many patients show features of both trajectories.
• Dynamic Changes: Trajectory designation may change as disease progresses.
• Biomarker Limitations: Existing biomarkers lack sufficient specificity.

Therapeutic Approaches

Trajectory-Directed Therapies

The different trajectories may require different therapeutic approaches:

For Gut-First (Body-First) PD

• Probiotics and prebiotics to modify gut microbiota
• Dietary interventions
• Anti-inflammatory agents targeting gut inflammation
• Fecal microbiota transplantation (FMT)

• Vagus nerve stimulation (VNS) - being explored
• Pharmacological agents targeting vagal signaling

• Agents that prevent alpha-synuclein aggregation in the ENS
• Immunotherapies targeting gut-derived pathology

For Brain-First PD

• Neuroprotective agents targeting dopaminergic neurons
• Mitochondrial protective strategies
• Anti-oxidant therapies
• Iron chelation (where applicable)

• Nasal irrigation and local treatments
• Olfactory training
• Intranasal therapeutic delivery

• Alpha-synuclein-targeted immunotherapies
• Gene therapy approaches
• Cell replacement therapies

Disease-Modifying Therapies in Development

| Therapy Type | Potential Trajectory Benefit | Stage |
|--------------|------------------------------|-------|
| Anti-α-Syn Immunotherapies | Both | Clinical trials |
| Small Molecule Aggreg inhibitors | Both | Preclinical/clinical |
| Microbiome Modulation | Gut-first | Clinical trials |
| Vagus Nerve Stimulation | Gut-first | Clinical trials |
| Gene Therapy | Both | Clinical trials |
| Cell Transplantation | Brain-first | Clinical trials |

Symptomatic Treatment Considerations

• Levodopa Response: May differ between trajectories
• Non-Motor Symptom Management: GI symptoms more prominent in gut-first; cognitive symptoms more prominent in brain-first
• Deep Brain Stimulation: May be beneficial for both, but optimal target selection may differ

Research Gaps and Future Directions

Unresolved Questions

Ongoing Research

• Large-scale biomarker studies in prodromal PD cohorts
• Imaging studies examining vagal nerve integrity
• Gut microbiome-intervention trials
• Post-mortem studies with detailed staging
• Genetic studies examining trajectory associations

Conclusion

The gut-first vs brain-first trajectory model represents a fundamental conceptual advance in understanding Parkinson's disease heterogeneity. This framework has important implications for:

• Early Diagnosis: Recognition of prodromal markers specific to each trajectory
• Biomarker Development: Trajectory-specific biomarker panels
• Therapeutic Development: Tailored disease-modifying approaches
• Clinical Trial Design: Stratified enrollment based on trajectory
• Personalized Medicine: Individualized treatment based on disease subtype

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Akkermansia muciniphila: A double-edged sword in life-stage-specific nutritional modulation of Parkinson's disease via the gut-brain axis.](https://pubmed.ncbi.nlm.nih.gov/41475022/) (2026 Apr) - Microbiological research
• [Mediterranean Diet, Polyphenols, and Neuroprotection: Mechanistic Insights into Resveratrol and Oleuropein.](https://pubmed.ncbi.nlm.nih.gov/41470875/) (2025 Dec 16) - Nutrients
• [Leveraging microbiome-based interventions to improve the management of neurodegenerative diseases: evidence for effects along the microbiota-gut-brain axis.](https://pubmed.ncbi.nlm.nih.gov/41459056/) (2025) - Frontiers in nutrition
• [A bibliometric analysis of acupuncture treatment and cognitive impairment.](https://pubmed.ncbi.nlm.nih.gov/40546257/) (2025) - Frontiers in neurology
• [Vitamin D and Neurological Health: Unraveling Risk Factors, Disease Progression, and Treatment Potential.](https://pubmed.ncbi.nlm.nih.gov/39440730/) (2025) - CNS & neurological disorders drug targets

Open Questions in Parkinson's Disease Research

Despite significant advances in understanding Parkinson's Disease pathogenesis, several fundamental questions remain unresolved. These knowledge gaps represent active areas of investigation and opportunity for future research.

Disease Initiation and Biomarkers

[

Immun

Trial

ReceThis section highlights recent publications relevant to this disease.

• [Akkermansia muciniphila: A double-edged sword in l- [Mediterranean Diet, Polyphenols, and Neuroprotection: Mechanistic Insights into Resveratrol and Oleuropein.](https://pubmed.ncbi.nlm.nih.gov/41470875/)** (2025 Dec 16) - Nutrients
• [Leveraging microbiome-based interventions to improve the management of neurodegenerative diseases: evidence for effects along the microbiota-gut-brain axis.](https://pubmed.ncbi.nlm.nih.gov/41459056/) (2025) - Frontiers in nutrition
• [A bibliometric analysis of acupuncture treatment and cognitive impairment.](https://pubmed.ncbi.nlm.nih.gov/40546257/) (2025) - Frontiers in neurology
• [Vitamin D and Neurological Health: Unraveling Risk Factors, Disease Progression, and Treatment Potential.](https://pubmed.ncbi.nlm.nih.gov/39440730/) (2025) - CNS & neurological disorders drug targets

References

References